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Cerebro spinal ﬂuidTuberculous meningitis and meningoencephalitis are rare and dangerous complications of infections with
mycobacteria-complex. Usually these are complications of systemic ﬂorid infection with Mycobacterium (M.)
tuberculosis. They are most often seen in immune compromised patients. The conﬁrmation of diagnosis can be
elaborate and delayed due to long-term culture requirements for M. tuberculosis. We present a female patient,
without history of immunosuppression, who was diagnosed with tuberculous meningoencephalitis using
ELISpot to detect immune reactivity against mycobacterial antigens with lymphocytes from cerebrospinal ﬂuid
(CSF). ELISpot with CSF derived lymphocytes seems to be an appropriate method to diagnose tuberculous men-
ingitis andmeningoencephalitis and tomake therapeutic decisions easier and earlier in atypical cases of infection
withM. tuberculosis.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculous meningitis and meningoencephalitis are rare and dan-
gerous complications of infections with mycobacteria-complex and
conﬁrmation of these diagnoses can be elaborated and often protracted
[1]. Evidence-based therapy with a long-term combination of four
tuberculostatic agents is accompanied by the risk of side effects affecting
multiple organ systems. Therefore, the initiation and continuation of
therapy should be substantiated by asmany clinical and laboratoryﬁnd-
ings as possible.
2. Materials and methods
2.1. ELISpot assays for peripheral blood and CSF
Venous blood was collected in lithium-heparin tubes and processed
regarding the instructions of the commercial T-SPOT.TB test (Oxford
Immunotec). Peripheral blood mononuclear cells (PBMCs) from the
cerebro spinal ﬂuid (CSF) were prepared according to Kösters et al.
2008 [2]. In short, native CSF was centrifuged at 465 g at room temper-
ature for 15min. After cell resuspension in AIM-Vmedium (life technol-
ogies) the centrifugation step was repeated. Finally, cells were
resuspended and counted in an automated cell counter (Vicell, BD) re-
garding cell count and viability. Further ELISpot analyses were done. This is an open access article underfollowing the instruction manual of the T-SPOT.TB test. In brief
250,000 PBMCs from human blood or 54,000 PBMCs from CSF were
stimulated with Mycobacterium (M.) tuberculosis speciﬁc antigens,
ESAT-6 and CFP-10, or PHA as positive control and medium as negative
control. Antigen speciﬁc T cells released interferon-γ (IFN-γ) after con-
tact with the antigen presenting cell. The released IFN-γ binds to the
precoated anti-IFN-γ antibody on the plate, and after incubation with
a second anti-IFN-γ antibody with a color reaction, the spots were visi-
ble on the plate.
The test is validated for blood with a sensitivity of 95.6% and a spec-
iﬁcity of 97.1%. Up to now, tests for other body ﬂuids, like CSF, are not
validated. Rather, they are done similar to tests with blood. In our case
we had only 54,000 PBMCs from CSF compared to 250,000 PBMCs for
ELISpot. This means that we used around 5 times less PBMCs albeit we
used the test interpretation for 250,000 PBMCs.
The test could be validated (blood) or interpreted (CSF) if the nega-
tive control showed less than ten spots and the positive control showed
more than 20 spots or spots too numerous to count (TNTC). The test re-
sult was positive in the case of more than 5 spots in the ESAT-6 or/and
CFP-10 stimulation and negative with 5 or less spots in the ESAT-6
and CFP-10 stimulation.
2.2. Literature search
Literature was searched via the database PubMed of the US National
Library of Medicine National Institutes of Health using the search terms
‘ELISpot’, ‘enzyme-linked immunospot’, ‘tuberculosis’, ‘tuberculous’,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and ‘extrapulmonary’ in various combinations by using the Boolean
operator AND.
3. Case report
A58 year old female patient, until that point healthy, presented to our
Department of Neurology via TEMPiS, a tele medical network for the re-
gion of South-East-Bavaria. She had suffered from a slight headache for
ten days before she was found confused and aphasic by her husband. In
the referring hospital she recovered quickly, and the initial diagnosis
was complex-focal epileptic seizure. In a cerebral computer tomography
(CT), a hypodense area in the left temporal lobe was seen. After cerebral
magnetic resonance imaging (MRI), a low-grade glioma or lymphoma
was suspected (Fig. 1A). The lumbar puncture revealed pleocytosis of
312/μl leukocytes with a mixed cytology consisting of 20% granulocytes,
30% lymphocytes, 40% monocytes and 10% macrophages. Lactate in CSF
was increased to 4.0 mmol/l (range 1.2 to 2.1) and the protein content
was heightened to 1242 mg/l (range 150 to 450). Subsequently, the pa-
tient was transferred to our hospital with a headache, meningism and
an elevated body temperature of 38 °C. The patient did not have neuro-
logical deﬁcits. She was treated with antibiotics and aciclovir for a
suspectedmeningoencephalitis. Because of the unclear etiology of the le-
sion, lumbar puncturewas performed three times excluding the presence
of atypical,malignant cells. The polymerase chain reactions (PCR) and an-
tibody indices for Streptococcus pneumoniae, Haemophilus inﬂuenzae,
Neisseria meningitidis, Streptococcus agalaetiae, Leptospira, Brucella,
Tick-borne encephalitis virus, Enterovirus, Varicella virus, Herpes virus
type I and type II, Aspergillus spp., Cryptococcus spp. and Bacteroides spp.
did not result in positive ﬁndings. CSF consistently showed high lactateFig. 1. CerebralMRI at onset of neurological symptoms (A) and after twoweeks of therapy
with anti-mycobacterial agents (B) in axial ﬂuid-attenuated inversion recovery (FLAIR)
images. (C) ELISpot for detection of immune reactivity against mycobacterial antigens
with lymphocytes from blood and CSF of a patient with tuberculousmeningoencephalitis.
Number of spots indicating T lymphocytes that have secreted IFN-γ in response to themy-
cobacterial antigens, ESAT-6 or/and CFP-10, aswell as to themitogen phytohemagglutinin
(PHA) from blood and CSF are shown. TNTC indicates too numerous to count.(3,2 mmol/l) and increasing mixed lympho-granulocytic pleocytosis
(314/μl) which led us to the suspicion of tuberculosis. The patient report-
ed that she was treated in hospital due to a pyelonephritis four months
ago. Furthermore, her father had suffered from lung tuberculosis. A rou-
tine X-ray of her lung post-speciﬁc lymph nodes had been found from
when shewas aged 20 years. Based on that history and the negativeﬁnd-
ings in screening for differential diagnoses, we started anti-tuberculous
treatment with isoniacide, rifampicin, pyrazinamide and levoﬂoxacin.
ELISpot from blood was positive for tuberculosis, but was not interpret-
able due to tuberculosis of the lung in the past. PCR for detection of M.
tuberculosis was done and direct microscopy was performed from spu-
tum, urine, serum and CSF, both with negative results (each three to six
times). After 12 days of therapy, the cell counts in CSF increased again.
In another cerebral MRI, new small contrast medium enhancing lesions
located left temporomesial, right frontolateral, and temporobasal were
found. Most likely, these were tuberculomas. At this point the diagnosis
was still uncertain due to inconclusive ﬁndings and the untypical clinical
manifestation. Thereforewedecided to performanELISpot fromCSF. For-
tunatelywehad a clear positive result despite the relatively small amount
of leukocytes in CSF.We used the standard ELISpot available for detection
of reactivity of T lymphocytes against M. tuberculosis speciﬁc antigens,
ESAT-6 and CFP-10 (Fig. 1C). Results were 58/250,000 spots per cells
for tuberculous protein CFP10 and 6/250,000 spots per cells for tubercu-
lous protein ESAT-6 with a positive control of 23/250,000 in CSF in
relation to 8/250,000 for ESAT-6 and 21/250,000 for CFP-10 with a posi-
tive control of TNTC in blood. We stated this ﬁnding as an indirect proof
that lymphocytes in CNS had contact to antigens of mycobacteria-com-
plex and continued the speciﬁc therapy against M. tuberculosis. On day
40 of treatment, the ﬁrst direct cultural detection ofM. tuberculosis, and
thus the diagnosis, were consolidated. During the course of events there
had not been any sign of basal meningitis, either clinically or by MRI.
The patient recovered within three weeks of initiation of treatment and
was released without symptoms from our hospital (Fig. 1B). After
six and nine months, CSF still showed a slight pleocytosis (13/μl) but
normalized lactate and protein content under continuous therapy for
12 months. There have not been any complications of therapy for the
time of treatment.
4. Discussion
As demonstrated by our case and the below summarized literature,
there is evidence for the effectiveness of ELISpot, for the detection of im-
mune reactivity against mycobacterial antigens with lymphocytes from
CSF in reducing the diagnostic delay caused by long incubation of cultures
for diagnosis of CNS infection byM. tuberculosis. It supports decisionmak-
ing for therapy initiation and continuation in immune competent, as well
as immunedeﬁcient patients, and could thereby even lead to a better out-
come, especially preventing the threatening deterioration often seen in
tuberculous meningitis or meningoencephalitis.
In all reviewed studies, the diagnosis of conﬁrmed CNS tuberculosis
(TBC) was based on the result of cultures forM. tuberculosis. In contrast,
diagnoses of highly probable, probable, or possible CNS TBC were diag-
nosed using a risk estimation consisting of age, length of history, white-
blood-cell count, CSF white blood cell count, and glucose as well as CSF
neutrophil proportion as ﬁrst described in 2002 by Thwaites et al. [3]. In
2005, this approach was evaluated in HIV negative patients with bacte-
rial and tuberculous meningitis revealing a sensitivity of 91.7% and
speciﬁcity of 79.7% in diagnosis in microbiologically proven cases,
respectively [4]. The decision for an empirical treatment was not inﬂu-
enced by ELISpot results in the reported studies, but made by clinical
features as well as imaging by CT or MRI and CSF ﬁndings. The results
of ELISpot were sometimes concealed by the attending physician to
avoid a bias. Nowadays, ELISpot with PBMC is an established diagnostic
adjunct in extrapulmonary tuberculosis. This is especially the case for
CNS TBC in immunocompetent patients [5]. As tuberculosis-speciﬁc T
cells tend to compartmentalize to the side of infection, a more sensitive
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CNS TBC compared to the abovementioned parameters. In 2008, Köster
et al. ﬁrst reported a patient with suspected TBC in whom ELIspot was
used not only with lymphocytes from blood but also from CSF [2]. The
authors reported that they were able to detect CNS infection byM. tu-
berculosis four weeks ahead of cultural detection. In the same year, the
ﬁrst prospective case series of ten patients with TBC with CNS infection
revealed a sensitivity of 90% and speciﬁcity of 100% [6]. Another pro-
spective analysis of 37 cases who were suspected to have CNS TBC re-
vealed a sensitivity and speciﬁcity of 75% for ELISpot with CSF derived
lymphocytes compared to 91% and 63% for blood derived lymphocytes,
however only seven patients were classiﬁed as conﬁrmed TBC by cul-
ture [7]. The combined sensitivity of ELISpot fromCSF and blood to diag-
nose CNS TBC was shown to be 94% with a negative likelihood ratio of
0.14 in 2010 by Kim et al. [8]. The speciﬁcity could be increased up to
100% when patients had a ratio of lymphocytes from CSF to lympho-
cytes from blood of 2 or higher. CSF ELISpot had a higher diagnostic
value than clinical prediction for CNS infection with TBC in immune
compromised patients in regions with endemic HIV infections. Even in
these patients in whom deﬁcient T cell reactivity is assumed, a sensitiv-
ity of 58% and speciﬁcity of 94%were reached by this approach [9]. Park
et al. showed in a study of 16 patients with TBC that the results of serial
analysis of ELISpot with lymphocytes from blood are overall variable
within an individual's immune response. Therefore the authors con-
clude that this approach is ineffective in predicting clinical response to
therapy. In contrast, presence of TBC speciﬁc T cells as demonstrated
by ELISpot in CSF in the ﬁrst six weeks of therapy is a predictor of ther-
apy failure [10].
Based on our case and the review of the literature, ELISpot from lym-
phocytes fromCSF for detection ofmycobacterial antigens seems to be a
very good method to diagnose CNS TBC and to bridge time until results
from bacterial cultures are available. The additive information obtained
by ELISpot from lymphocytes of CSF can be used to start with early anti-
mycobacterial treatment.
5. Conclusion
ELISpotwith lymphocytes fromCSF for detection of immune reactiv-
ity against mycobacterial antigens should be an essential part of the
routine diagnostic pathway in cases with meningitis or meningoen-
cephalitis possibly caused byM. tuberculosis.Author contributions
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